Background. There is a general consensus that elevated serum beta-2 microglobulin (B2M) levels measured at a single timepoint are significantly associated with mortality in patients on maintenance dialysis. To date, the majority of prior studies that have examined B2M-associated mortality have been conducted in prevalent hemodialysis patients with little residual renal function (RRF). However, studies in incident peritoneal dialysis (PD) patients are lacking. Moreover, changes in serum B2M levels over time have not been considered in this population. Methods. We examined the association of time-updated and baseline serum B2M levels with mortality in a 10-year cohort of 725 incident PD patients who were maintained on dialysis between January 2006 and December 2011 using Cox proportional hazards regression analyses. Patients were categorized into tertiles according to B2M levels. Results. During a median follow-up of 38 (interquartile range 23-64) months, 258 (35.4%) deaths occurred, including 106 (14.6%) and 86 (11.9%) deaths from cardiovascular and infectious causes, respectively. The lowest B2M tertile was associated with a higher risk of all-cause and infectious mortality compared with the middle tertile: the hazard ratios (95% confidence interval) for all-cause deaths were 2.12 (1.38-3.26) and 2.20 (0.96-5.05) in time-varying analyses and 1.52 (1.07-2.17) and 2.41 (1.19-4.88) in baseline analyses. Subgroup analyses showed that this association was particularly observed in females, older patients, those with comorbidities such as diabetes, a lower body mass index, lower albumin levels or those with higher RRF (all P for interactions <0.05). Conclusions. In incident PD patients, lower B2M levels were independently associated with overall and infectious mortality. These associations can be potentially modified by malnutrition, inflammation and RRF.
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I N T R O D U C T I O N
Beta-2 microglobulin (B2M), an 11 800 Da polypeptide protein that is present on the surface of all nucleated human cells, is essential for the generation of the major histocompatibility class I family to facilitate antigen presentation [1, 2] . B2M homeostasis is tightly regulated in the body of healthy individuals; it is generated at a constant rate and is exclusively eliminated by the kidneys [3] . However, serum B2M levels are typically elevated in patients with impaired kidney function, particularly those on maintenance dialysis with anuria or low residual renal function (RRF) [4] [5] [6] [7] [8] [9] [10] . Interestingly, recent studies have evaluated the impact of serum B2M levels on mortality in dialysis patients and found that higher serum B2M levels were associated with worse survival [11] [12] [13] [14] . It has been widely accepted that B2M is a marker of overall middle-molecular uremic toxins encompassing as yet unidentified but possibly more toxic other solutes [15] . Nonetheless, enhanced dialytic clearance of B2M has not convincingly been translated into improved survival in randomized controlled trials on high flux dialysis [8, 16] and on-line hemodiafiltration [17] [18] [19] . This has highlighted the question of whether decreasing serum B2M levels is truly beneficial in patients with end-stage renal disease (ESRD).
To date, the majority of studies that have investigated the association between serum B2M levels and mortality have been conducted in hemodialysis patients [11] [12] [13] 20] , but this association remains unclear in patients receiving peritoneal dialysis (PD) [14] . Moreover, many studies measured only B2M levels and other important factors relevant to clinical outcomes at single time-point; thus, these studies have been limited by a failure to account for changes in serum B2M levels over time [13, 14, 20] . Given that all previous studies exclusively included prevalent hemodialysis patients with little RRF or analyzed pooled data from prevalent and incident PD patients [11] [12] [13] [14] 20] , it remains unanswered whether high serum B2M levels can also adversely affect clinical outcomes in incident dialysis patients with sufficient RRF. Therefore, we conducted this study to evaluate the association of changes in serum B2M levels over time with mortality in a 10-year contemporary cohort of 725 incident PD patients. We hypothesized that the impact of serum B2M levels on mortality in incident PD patients might differ from that of the counterpart of prevalent hemodialysis patients based on the well-known notion that PD provides a better conservation of endogenous RRF [21, 22] but a limited dialytic clearance of B2M [23] [24] [25] .
M A T E R I A L S A N D M E T H O D S

Study population and data source
The present study population was comprised of all adult (>18 years of age) patients with ESRD who initiated PD at Yonsei University Severance Hospital or National Health Insurance Service Ilsan Hospital between January 2006 and December 2011. Patients who had been treated with hemodialysis, who received a kidney transplant before PD initiation, or who started PD due to acute kidney injury or congestive heart failure were excluded. After exclusion of those who did not have serum B2M measurements during the first 6 months of PD initiation, patients were further excluded if they had an outlier B2M concentration below the 0.5th or above the 99.5th percentile of observed values. Accordingly, the final study population consisted of 725 incident PD patients ( Figure 1 ).
All data were obtained from the electronic medical records of dialysis facilities. Both demographic and clinical data were collected at the beginning of PD. Laboratory measurements were performed monthly to quarterly throughout the entire study period; data collected included serum lipid profiles, albumin, ferritin and C-reactive protein (CRP) levels. Serum B2M concentrations were regularly measured every 6 months using a latex immunoassay. The dialysis dose, estimated by weekly total and peritoneal K t /V urea using urea kinetic model, and the residual glomerular filtration rate (GFR), calculated as the average urea and creatinine clearance from a 24-h urine collection, were measured at least annually. To minimize measurement variability, all repeated measurements for each 6-month interval from the date of dialysis therapy initiation were averaged and incorporated as time-varying values in all models. The study was performed in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of Ilsan Hospital Clinical Trial Center. Given the nonintrusive nature of this research and the anonymity of the patients studied, the requirement for written consent was waived.
Exposure and outcome ascertainment
The exposures of interest were serum B2M levels, and we examined both time-dependent and baseline levels to determine the short-term and long-term associations between serum B2M level and risk of death [26] . Given the possible nonlinear relationship of B2M levels with mortality rates, serum B2M levels were treated as a categorical variable. Thus, patients were divided into the following three categories (low, middle and high) based on tertiles of serum B2M levels: <9.5, 9.5 to <21.7 (reference group) and !21.7 mg/L of time-varying B2M levels and <2.1, 2.1 to <13.3 (reference group) and !13.3 mg/L of baseline serum B2M levels, respectively.
The primary outcome of interest was all-cause mortality. We also examined the association of B2M levels with cause-specific mortality, including cardiovascular (CV) and infectious death, which was assessed by manual chart reviews to identify the main cause of death based on the following definitions: CV death was defined as death from coronary artery disease, congestive heart failure or cerebrovascular disease, and infectionrelated death was considered as death that could be attributed to a documented or strong clinical suspicion of various infection such as pneumonia, peritonitis (PD-related or surgical), pyelonephritis, tuberculosis, endocarditis, meningitis or sepsis (septicemia). Patients were censored at the time of kidney transplantation or when they were switched to hemodialysis, lost to follow-up, or transferred to other dialysis clinics. Patients were followed until 31 December 2015.
Statistical analysis
We estimated the association between serum B2M levels categorized into tertiles and mortality using Cox proportional hazard regression models with four incremental levels of adjustment: (i) Model 1: demographic and clinical characteristics of age, sex and eight comorbid conditions (diabetes, hypertension, coronary artery disease, stroke, congestive heart failure, peripheral artery disease, arrhythmia and dementia); (ii) Model 2: Model 1 plus malnutrition and inflammation indices that included body mass index (BMI, body weight in kilograms divided by height in meters squared), serum total cholesterol, albumin, ferritin and CRP levels, percentage of lean body mass (%LBM) and normalized protein catabolic rate (nPCR); (iii) Model 3: Model 2 plus residual GFR; and (iv) Model 4 (fully adjusted model): Model 3 plus dialysis modality (automated PD) and dose (peritoneal K t /V urea ). All laboratory data, including B2M levels, were updated every 6 months over the entire follow-up period to account for changes in serum B2M levels over time. Thus, these were incorporated as time-dependent variables in time-varying analyses. For the time-dependent analyses, the median [interquartile range (IQR)] number of B2M measurements that contributed to each 6 months-averaged metric per patient was 5 (IQR 3-9). To evaluate the consistency of study findings, we performed a sensitivity analysis by Beta-2 microglobulin and mortality categorizing serum B2M levels into quartiles as follows: timevarying B2M levels, <3.1, 3.1 to <15.1, 15.1 to <26.1 and !26.1 mg/L; and baseline B2M levels, <1.6, 1.6 to <9.6, 9.6 to <15.1 and !15.1 mg/L. In addition, we also examined the association between continuous B2M levels and overall mortality by using restricted cubic spline models with four knots. For causespecific mortality, competing risk regression analyses were used to account for corresponding competing events. Non-CV deaths were competing events for CV mortality, and noninfectious deaths were competing events for infectious mortality [27] .
We then examined the association between time-varying serum B2M levels and all-cause mortality across the following clinically relevant subgroups: age (<60 versus !60 years), sex, diabetes, BMI ( . To examine any possible effect modification of these covariates, we also tested heterogeneity by incorporating the interaction term between a given variable and the three B2M categories into the fully adjusted Cox models. Missing laboratory values (<0.5% for all tests except dialysis parameters) were excluded from multivariate models without imputation. All mortality associations were expressed as hazard ratios (HRs) and 95% confidence intervals (CIs). Data from descriptive analyses were summarized using means (6standard deviation, SD), medians (IQR) or proportions. All statistical analyses were performed using Stata version 14.2 (Stata Corporation, College Station, TX, USA).
R E S U L T S
Study population
The baseline characteristics of patients according to serum B2M levels at the time of PD initiation are summarized in Table 1 . The median patient age was 61 (IQR 50-70) years; 55% of the study population was male and 56% were diabetic. The mean and median baseline values for observed B2M levels were 9.6 (SD 8.3) and 9.6 (IQR 1.6-15.0) mg/L, respectively. Patients with higher baseline B2M levels had more hypertension, higher BMI and higher CRP levels, whereas they had lower nPCR, %LBM, albumin levels and total cholesterol concentrations. They also had lower achieved dialysis adequacy and residual GFR. The B2M levels at baseline were not different according to diabetic status (Supplementary data, Table S1 ). During a median follow-up of 38 (IQR 23-64) months (2881 patient-years of follow-up), 258 (35.4%) all-cause deaths, 106 (14.6%) CV deaths and 86 (11.9%) infectious deaths occurred, with crude mortality rates of 89.5 (95% CI 79.3-101.2), 36.8 (95% CI 30.4-44.5) and 29.8 (95% CI 24.1-36.9) deaths per 1000 patientyears, respectively (Supplementary data, Table S2 ).
B2M levels and all-cause mortality
Compared with the middle reference tertile, the highest time-dependent B2M level was associated with significantly higher all-cause mortality risk in a model adjusted for demographic parameters (Model 1). However, this association was attenuated after adjusting for malnutrition and inflammation surrogates (Model 2). Furthermore, it was no longer significant after adjustment for residual GFR (Model 3). In contrast, the increased risk of all-cause death in the lowest B2M tertile became more evident even after incremental adjustments in time-varying analyses: the HRs were 2.12 (95% CI Figure 2A) . A similar pattern was observed in baseline B2M level-based models (Table 2 and Figure 2B ).
In sensitivity analyses performed using four categories based on serum B2M level quartiles the increased risk of death in the lowest quartile of B2M level remained consistent (Supplementary data, Table S3 and Figure S1 ). In addition, a similar trend was observed in fully adjusted cubic spine models using continuous B2M levels in which incrementally lower B2M levels were associated with progressively higher mortality risk in both baseline and time-varying analyses (Supplementary data, Figure S2 ).
In subgroup analyses, however, this association was most robust among patients with high comorbid conditions, particularly in the following subgroups: females; older individuals; those with diabetes, lower BMIs and lower albumin levels ( Figure 3) . Notably, the lowest serum B2M tertile was associated with significantly higher risk of mortality particularly among patients with preserved RRF, whereas the highest serum B2M tertile tended to be associated with higher mortality only in those with reduced RRF at baseline (residual GFR <4.0 mL/ min/1.73 m 2 ).
B2M levels and cause-specific mortality
Finally, we evaluated which of CV-related death or infectious death more accounts for the increased overall mortality risk associated with lower B2M levels ( Table 3 ). There was no significant association between serum B2M levels and risk of CV death. However, the lowest B2M tertile was associated with significantly higher risk of infectious mortality in time-varying analyses (Model 2; HR 2.45, 95% CI 1.14-5.26) and in baseline analysis (Model 4; HR 2.41, 95% CI 1.19-4.88) (Figure 4 ).
D I S C U S S I O N
In this large cohort of incident PD patients over a 10-year follow-up, lower B2M levels were associated with significantly increased risk of death. This association was particularly evident in poorly nourished or inflamed patients. Interestingly, the increased risk of mortality associated with lower B2M levels was also found in patients with preserved RRF. Our findings suggest that lower B2M levels can be a useful predictor of death in incident PD patients, and this association can be modified by malnutrition, inflammation or RRF.
Because B2M is removed exclusively by the kidneys, its levels substantially increase in dialysis-dependent ESRD patients [4] [5] [6] [7] [8] [9] [10] . Beyond the role of excess B2M in dialysis-related amyloidosis [28] , recent studies have suggested that high serum B2M levels are predictors of all-cause mortality in patients on maintenance dialysis [11] [12] [13] [14] . Although the mechanism underlying the association of B2M with poor survival involves the middle molecule hypothesis as a proxy of other uremic toxins, interpretation of serum B2M levels in patients with ESRD is complicated by nutritional status, inflammation and RRF [29, 30] . Indeed, in our study, the mortality risk associated with elevated B2M levels was greatly attenuated after adjustment for multiple confounding factors that related to malnutrition and inflammatory surrogates (Model 2, Table 2 ), and it was no longer significant after adjusting for RRF (Model 3, Table 2 ). These findings suggest that the association between higher B2M levels and increased mortality might be partially attributable to the confounding role of malnutrition, high inflammation and low RRF. 
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FIGURE 2: Association of time-varying (A) and baseline (B) B2M level tertiles with all-cause mortality (HRs and 95% CI error bars). Adjustments in Model 1: age, sex and comorbid conditions (diabetes, hypertension, coronary artery disease, stroke, congestive heart failure, peripheral artery disease, arrhythmia and dementia); Model 2: Model 1 plus malnutrition and inflammation indices that included BMI, serum total cholesterol, albumin, ferritin and CRP levels, %LBM and nPCR; Model 3: Model 2 plus residual GFRs; Model 4: Model 3 plus dialysis modality (automated PD) and dose (peritoneal K t /V urea ).
Beta-2 microglobulin and mortality Interestingly, we showed that lower serum B2M levels were paradoxically associated with increased risk of death even after extensive adjustment including RRF. Although the mechanisms responsible for these observations remain unclear, there are several explanations of the discrepancy between our findings and those reported by prior investigators [11] [12] [13] [14] . The first and most important reason may be the different RRF among patients included in various studies, as RRF is considered a major determinant of serum B2M concentration, even in patients receiving maintenance dialysis [30] . Most studies included prevalent patients with anuria or extremely low RRF [11] [12] [13] [14] 20] , whereas our study included only incident patients with well-preserved RRF. This is particularly evident in the fact that our study subjects had considerably lower B2M levels with a median value of 9.6 mg/L, than those in other study cohorts. In fact, in a study by McCarthy et al. [31] , serum B2M concentrations were 2-fold higher in hemodialysis patients with a GFR <1 mL/min/1.73 m 2 than in those with a GFR of 4-5 mL/min/1.73 m 2 . Another meta-analysis using large-scale modeling of hemodialysis trials demonstrated that enhanced dialytic removal of B2M could materially affect serum B2M levels and the mortality risk associated with high B2M FIGURE 3: HRs (and 95% CI error bars) of all-cause mortality for the lowest (A: <9.5 mg/L) and the highest (B: !21.7 mg/L) tertiles versus the reference group (middle tertile, 9.5 to <21.7 mg/L) of time-varying serum B2M levels, overall and across clinically relevant subgroups. Models were adjusted for age, sex, comorbid conditions (diabetes, hypertension, coronary artery disease, stroke, congestive heart failure, peripheral artery disease, arrhythmia and dementia), BMI, serum total cholesterol, albumin, ferritin, CRP levels, %LBM, nPCR, automated PD, peritoneal K t /V urea and residual GFRs. levels only when residual renal clearance was <2 mL/min/ 1.73 m 2 [32] . In agreement with these findings, we also found that the highest serum B2M tertile tended to be associated with higher mortality only in patients with reduced RRF (residual GFR <4.0 mL/min/1.73 m 2 ) at baseline (Figure 3) . Additionally, in our study, the paradoxical association of higher death risk with lower B2M levels was observed particularly among patients with preserved RRF, which suggests that the association between B2M and mortality can be modified by RRF. However, it is possible that as RRF is being lost, B2M levels increase accordingly and thus may have different meaning. In anuric patients on long-term dialysis, increased inflammation and poor nutritional status become evident and may emerge to interact with B2M. Given that our study included only incident patients and that the mean observation period of 47.7 months was relatively short, it is possible that B2M levels may not have reached the critical point needed to have significant impact on adverse clinical outcomes. In fact, the median B2M value in our cohort was only 19.4 mg/L, even at the last visit. Presumably, long-lasting RRF provided by PD may result in relatively lower A B FIGURE 4: Association of time-varying (A) and baseline (B) B2M levels in tertiles with infectious mortality (HRs and 95% CI error bars). Adjustments in Model 1: age, sex and comorbid conditions (diabetes, hypertension, coronary artery disease, stroke, congestive heart failure, peripheral artery disease, arrhythmia and dementia); Model 2: Model 1 plus malnutrition and inflammation indices that included BMI, serum total cholesterol, albumin, ferritin and CRP levels, %LBM and nPCR; Model 3: Model 2 plus residual GFRs; Model 4: Model 3 plus dialysis modality (automated PD) and dose (peritoneal K t /V urea ). B2M levels. Further long-term studies are required to examine whether the clinical implication of B2M may differ in longterm dialysis patients with complete absence of RRF. Another potential explanation for the discrepancy among studies is that the impact of B2M concentrations on mortality may differ according to dialysis modality. In PD, dialytic removal of B2M is small due to the overall slow rate of convective transport and dialysate flow rate, despite the peritoneal membrane being highly permeable to small proteins [23] [24] [25] . In fact, dialytic clearance of B2M was significantly higher by high-flux hemodialysis compared with PD (29 versus 6 L/week per 1.73 m 2 ) [25] . Therefore, it is possible that intrinsic renal clearance (i.e. RRF) as well as other factors related to its generation (e.g. nutritional status or inflammation) may be more important than dialytic removal by PD in determining serum B2M concentrations among patients receiving PD. Despite the fact that the B2M kinetics in PD is distinct from those in hemodialysis, the impact of serum B2M levels on the mortality in PD patients has been underexplored. Of note, two studies, including ours, yielded conflicting results on the association of serum B2M levels with mortality among patients undergoing PD. A previous observational study by Koh et al. [14] using the Korean ESRD cohort database showed that HRs for all-cause mortality was 1.02 (95% CI 1.01-1.04, P ¼ 0.006) per 1 mg/L increase in B2M after adjusting for nutritional and inflammatory indices, even though this association was not significant after further adjusting for RRF. In contrast, we showed that the relationship between serum B2M concentration and survival was not linear and that a lower B2M level, rather than a higher B2M, was associated with significantly higher mortality, even after adjusting for RRF. It is important to point out that the characteristics of the patients in the studies qualitatively differed. Indeed, in the study by Koh et al., 62% of patients were anuric, whereas the majority of our subjects had substantial RRF. Additionally, the baseline median serum B2M values (23.6 mg/L) were much higher in the former study than in our cohort. This may explain why their findings were similar to those observed in anuric hemodialysis patients. Finally, another possible explanation for the seemingly paradoxical associations observed in this study is the time-dependency of the deleterious effects imparted by accumulated B2M [26] . Given that this toxin typically takes harmful effect over an extended period of time, the possibility that serum B2M levels in the short term are more reflective of other factors such as nutrition and RRF cannot be discounted. In this study, mortality risk related to lower B2M levels was greater in time-varying analyses than in baseline analyses (Table 2 ). In contrast, higher mortality associated with elevated B2M values was observed only in baseline cubic spline models (Supplementary data, Figure S2 ). Hence, worse outcomes in patients with lower B2M levels can be observed in the short term, while accumulating B2M comes into play at a later time-point as seen in previous studies [11] [12] [13] [14] .
Although the mechanisms responsible for increased mortality observed in patients with lower B2M levels are unclear, the majority of the deaths in these patients were related to infectious disease. Given that B2M is a component of the major histocompatibility class I family, which facilitates antigen presentation and is considered a marker for the activation of the cellular immune system [1] , it can be postulated that patients with extremely low B2M levels represent impaired immunity, and can thus be vulnerable to infectious complications. This hypothesis can partially explain the increased risk of death in the lowest B2M tertile, particularly in new PD patients with preserved RRF. Prior to initiation of dialysis, patients may become malnourished because of protein restriction, uremiaassociated poor oral intake and increased catabolism despite deteriorating but functioning kidneys. In this setting, B2M levels may not necessarily be increased due to substantial RRF. Rather, malnutrition can suppress overall immune system, resulting in suppression of B2M production. Our findings of greater risk of death associated with lower B2M levels in poorly nourished or inflamed patients can further support this hypothesis. However, to date, there is no definite proof of alterations in the generation and metabolism of B2M according to nutritional status or RRF, especially in the early phase after dialysis initiation. Hence, it is vital that future studies focus on this issue to identify the underlying mechanisms responsible for poor outcomes in incident PD patients with lower B2M concentrations.
The strengths of our study include its examination of a large cohort of incident PD patients, the availability of time-varying measures of B2M and other important factors relevant to clinical outcomes, and its extensive adjustments and subgroup analyses. However, several limitations of our study should be discussed. First, the present findings are observational in nature, which precludes conclusions concerning causality. In addition, although our findings unveiled the new aspect of B2M, it is unknown how B2M measurement can be implemented in clinical practice. At least, we hope to alert physicians to the possibility that low B2M level associated with comorbid conditions can have a different clinical implication with respect to adverse outcomes. Second, as in all observational studies, we cannot exclude the possibility of residual confounding. In particular, we did not measure B2M peritoneal clearance or peritoneal membrane transport phenotype, which can be associated with both serum B2M levels and poor outcomes in PD patients. Further studies are warranted to examine the relationship between peritoneal clearance of B2M and mortality according to membrane transport status. Third, the proportion of diabetic patients (55.7%) was relatively high in this study, which could lead to bias. However, there was no significant difference in baseline B2M levels between diabetics and non-diabetics (Supplementary data, Table S1 ). While we cannot completely exclude a possible interaction between diabetes and B2M in our findings, it is less likely that our results can be solely due to the high proportion of diabetics included in our cohort. Finally, considering the uniform population of this study (i.e. an Asian population), our results may not be completely generalizable to other races and ethnicities.
In conclusion, in incident PD patients with well-preserved RRF, lower B2M levels were independently associated with a higher risk of all-cause and infectious mortality, particularly in those with a high number of comorbid conditions. Thus, physicians should pay more attention to patients with low B2M level, particularly when they are malnourished, or complicated by infection. Although questions related to causality and the mechanisms underlying these findings remain unanswered, B2M may have different clinical implications depending on RRF. Thus, future studies are needed to investigate the pathways through which low B2M levels adversely impact survival among dialysis patients with preserved RRF.
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